Eli Lilly’s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China
Eli Lilly and Company (NYSE: LLY) announced that the National Medical Products Administration (NMPA) has approved...
Company
Guangji Pharma to Raise $87 Million via Private Placement to Controlling Shareholder
Hubei Guangji Pharmaceutical Co., Ltd. (SHE: 000952) announced plans for a private placement of up to...
uBriGene Biosciences Partners with BriSTAR Immunotech on Universal STAR-T Cell Therapy CDMO
uBriGene Biosciences, a China-based advanced therapy medicinal product (ATMP) CDMO, has entered a strategic partnership...
Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal
Newsoara BioPharma Co., Ltd. and vTv Therapeutics LLC have expanded their strategic collaboration, with Newsoara...
Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care
Siemens Healthineers AG (ETR: SHL) and Northwestern Medicine have officially launched the first phase of a...
SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer
SciClone Pharmaceuticals Inc. (HKG: 6600) announced that the National Medical Products Administration (NMPA) has accepted for...
Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III
Cascade Pharmaceuticals, Inc., a Shanghai-based sino-foreign joint venture, has closed a RMB 500 million (USD 72.34 million)...
Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA)...
Takeda’s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist
Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced that the U.S. Food and Drug Administration (FDA)...
GSK’s RSV Vaccine Filing Accepted by NMPA for China Market Entry
GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the Center for Drug Evaluation (CDE) of China’s NMPA...
uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases
uBriGene Biosciences, a China-based advanced therapy medicinal product (ATMP) CDMO, has entered a strategic partnership...
AstraZeneca Reports 8% Revenue Growth to $58.7 Billion in 2025; Oncology Leads with 17% Surge
AstraZeneca PLC (AZ, NASDAQ: AZN) delivered strong 2025 financial results, with total revenues rising 8% year-on-year...
Gilead Reports 2025 Revenue Growth to $29.4 Billion on HIV Strength; Veklury Plunges 49%
Gilead Sciences, Inc. (NASDAQ: GILD) announced fourth quarter and full-year 2025 financial results, with total revenues...
Pfizer’s Cresemba Wins NMPA Pediatric Approval for Invasive Fungal Infections
Pfizer Inc. (NYSE: PFE) announced that the National Medical Products Administration (NMPA) has approved an indication...
Eli Lilly’s Omvoh Wins NMPA Approval for Crohn’s Disease and Ulcerative Colitis in China
The National Medical Products Administration (NMPA) has approved Eli Lilly and Company’s (NYSE: LLY) Omvoh (mirikizumab),...
China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million
China Resources Pharmaceutical Group Co., Ltd. (HKG: 3320) announced plans to sell a 17.87% stake in...
Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun GeneScience...
Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder
Sanofi (NASDAQ: SNY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device
Hangzhou Tangji Medical Technology Co., Ltd. has filed its IPO prospectus with the Hong Kong...
Eisai Biogen’s LEQEMBI Subcutaneous Autoinjector Wins NMPA Priority Review in China
Eisai Co., Ltd. and Biogen Inc. (NASDAQ: BIIB) announced that the Biologics License Application (BLA) for...